TAVI术后感染性心内膜炎的外科治疗结局
基于TAVI术后感染性心内膜炎国际登记研究,584例确诊患者中111例(19%)接受心脏手术联合抗生素治疗,473例(81%)仅用抗生素。粗分析和调整选择偏倚及不死时间偏倚后,心脏手术均未与住院或1年全因死亡率降低相关。死亡预测因素包括 logistic EuroSCORE I、金黄色葡萄球菌、急性肾衰竭、持续菌血症和感染性休克。
要点
- TAVI术后感染性心内膜炎患者多数仅用抗生素治疗,心脏手术未显示生存获益。
- 调整前后心脏手术与住院及1年全因死亡率均无显著关联。
- 高死亡率与患者特征、病原体及感染性心内膜炎相关并发症密切相关。
核心结论
- 在TAVI术后感染性心内膜炎患者中,心脏手术与抗生素治疗相比未改善住院或1年全因死亡率。
研究设计与样本
- 研究使用TAVI术后感染性心内膜炎国际登记数据,纳入584例确诊患者,其中心脏手术联合抗生素组111例(19%),仅抗生素组473例(81%)。
- 采用粗分析和逆概率治疗加权分析评估心脏手术与药物治疗对1年全因死亡率的影响。
主要发现
- 粗队列中,心脏手术联合抗生素组与仅抗生素组相比,住院死亡率HRunadj为0.85(95%CI 0.58-1.25),1年全因死亡率HRunadj为0.88(95%CI 0.64-1.22)。
- 调整选择偏倚和不死时间偏倚后,心脏手术联合抗生素组与仅抗生素组相比,住院死亡率HRadj为0.92(95%CI 0.80-1.05),1年全因死亡率HRadj为0.95(95%CI 0.84-1.07)。
- 分别分析有无TAVI人工瓣膜受累的患者时,结果相似。
- 住院和1年全因死亡率的预测因素包括 logistic EuroSCORE I、金黄色葡萄球菌、急性肾衰竭、持续菌血症和感染性休克。
临床怎么用
- 对于TAVI术后感染性心内膜炎患者,不应仅因诊断而常规选择心脏手术,需综合评估患者特征、病原体和并发症。
- 金黄色葡萄球菌感染、急性肾衰竭、持续菌血症和感染性休克提示高死亡风险,应加强关注。
局限性
- 研究为登记研究,存在选择偏倚和残留混杂可能,已通过逆概率治疗加权调整但无法完全消除。
- 心脏手术组样本量较小(111例),可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal treatment of patients developing infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI) is uncertain. OBJECTIVES: The goal of this study was to investigate the clinical characteristics and outcomes of patients with TAVI-IE treated with cardiac surgery and antibiotics (IE-CS) compared with patients treated with antibiotics alone (IE-AB). METHODS: Crude and inverse probability of treatment weighting analyses were applied for the treatment effect of cardiac surgery vs medical therapy on 1-year all-cause mortality in patients with definite TAVI-IE. The study used data from the Infectious Endocarditis after TAVI International Registry. RESULTS: Among 584 patients, 111 patients (19%) were treated with IE-CS and 473 patients (81%) with IE-AB. Compared with IE-AB, IE-CS was not associated with a lower in-hospital mortality (HRunadj: 0.85; 95% CI: 0.58-1.25) and 1-year all-cause mortality (HRunadj: 0.88; 95% CI: 0.64-1.22) in the crude cohort. After adjusting for selection and immortal time bias, IE-CS compared with IE-AB was also not associated with lower mortality rates for in-hospital mortality (HRadj: 0.92; 95% CI: 0.80-1.05) and 1-year all-cause mortality (HRadj: 0.95; 95% CI: 0.84-1.07). Results remained similar when patients with and without TAVI prosthesis involvement were analyzed separately. Predictors for in-hospital and 1-year all-cause mortality included logistic EuroSCORE I, Staphylococcus aureus, acute renal failure, persistent bacteremia, and septic shock. CONCLUSIONS: In this registry, the majority of patients with TAVI-IE were treated with antibiotics alone. Cardiac surgery was not associated with an improved all-cause in-hospital or 1-year mortality. The high mortality of patients with TAVI-IE was strongly linked to patients' characteristics, pathogen, and IE-related complications.
引用
- Mangner N, del Val D, Abdel-Wahab M, et al. Surgical Treatment of Patients With Infective Endocarditis After Transcatheter Aortic Valve Implantation. J Am Coll Cardiol. 2022. PMID: 35210032. doi:10.1016/j.jacc.2021.11.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。